162 related articles for article (PubMed ID: 27044771)
1. Regression of esophageal varices during entecavir treatment in patients with hepatitis-B-virus-related liver cirrhosis.
Jwa HY; Cho YK; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU; Kim BS; Lee BW; Song BC
Clin Mol Hepatol; 2016 Mar; 22(1):183-7. PubMed ID: 27044771
[TBL] [Abstract][Full Text] [Related]
2. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
3. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
4. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
[TBL] [Abstract][Full Text] [Related]
5. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
6. Baseline Hepatitis B Virus DNA Level is a Promising Factor for Predicting the 3 (rd) Month Virological Response to Entecavir Therapy: A Study of Strict Defined Hepatitis B virus Induced Cirrhosis.
Xu Y; Wu XN; Shi YW; Wei W; Yang AT; Sun YM; Zhao WS; You H
Chin Med J (Engl); 2015 Jul; 128(14):1867-72. PubMed ID: 26168824
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.
Suzuki F; Hosaka T; Suzuki Y; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
J Gastroenterol; 2019 Feb; 54(2):182-193. PubMed ID: 30136216
[TBL] [Abstract][Full Text] [Related]
8. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model.
Tada T; Toyoda H; Yasuda S; Miyake N; Kumada T; Kurisu A; Ohisa M; Akita T; Tanaka J
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1452-1459. PubMed ID: 31082998
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
[TBL] [Abstract][Full Text] [Related]
10. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
[TBL] [Abstract][Full Text] [Related]
11. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
12. Regression of esophageal varices and splenomegaly in two patients with hepatitis-C-related liver cirrhosis after interferon and ribavirin combination therapy.
Lee SJ; Cho YK; Na SY; Choi EK; Boo SJ; Jeong SU; Song HJ; Kim HU; Kim BS; Song BC
Clin Mol Hepatol; 2016 Sep; 22(3):390-395. PubMed ID: 27572075
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
[TBL] [Abstract][Full Text] [Related]
14. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults.
Lee HW; Park JY; Ahn SH
Expert Rev Gastroenterol Hepatol; 2016; 10(2):177-86. PubMed ID: 26610256
[TBL] [Abstract][Full Text] [Related]
16. Cirrhosis has no impact on therapeutic responses of entecavir for chronic hepatitis B.
Wang PC; Wei TY; Tseng TC; Lin HH; Wang CC
Eur J Gastroenterol Hepatol; 2017 Aug; 29(8):946-950. PubMed ID: 28538267
[TBL] [Abstract][Full Text] [Related]
17. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
18. Entecavir Monotherapy Prevents Hepatitis B Virus Recurrence After Liver Transplant for Chronic Hepatitis B Patients: A Long-Term Retrospective Study.
Liu Y; Ho WI; Deng F; Peng S; Lau WY; Chen H
Transplant Proc; 2021 Jun; 53(5):1700-1706. PubMed ID: 34030872
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
[TBL] [Abstract][Full Text] [Related]
20. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
Wong GL; Wong VW; Chan HY; Tse PC; Wong J; Chim AM; Yiu KK; Chu SH; Chan HL
Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]